Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03326258
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:52.011217+00:00
Published At
2018-07-18T00:00:00+00:00
Record Updated At
2018-07-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Malignant Solid Neoplasm", "Estrogen Receptor Negative", "GPNMB Positive", "HER2/Neu Negative", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Progesterone Receptor Negative", "Stage III Breast Cancer AJCC v7", "Stage III Cutaneous Melanoma AJCC v7", "Stage III Uveal Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7", "Triple-Negative Breast Carcinoma", "Unresectable Solid Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-07-18"
protocolSection.identificationModule.nctId
"NCT03326258"
protocolSection.identificationModule.officialTitle
"Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Negative (protocolSection.conditionsModule.conditions)
  • GPNMB Positive (protocolSection.conditionsModule.conditions)
  • HER2/Neu Negative (protocolSection.conditionsModule.conditions)
  • Metastatic Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Metastatic Melanoma (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor Negative (protocolSection.conditionsModule.conditions)
  • Stage III Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage III Cutaneous Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage III Uveal Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Cutaneous Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Cutaneous Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Cutaneous Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Cutaneous Melanoma AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Uveal Melanoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Triple-Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Solid Neoplasm (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.